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Apraxia of speech is a disorder of speech motor planning and/or programming that is distinguishable from aphasia and
dysarthria. It most commonly results from vascular insults but can occur in degenerative diseases where it has typically been
subsumed under aphasia, or it occurs in the context of more widespread neurodegeneration. The aim of this study was to
determine whether apraxia of speech can present as an isolated sign of neurodegenerative disease. Between July 2010 and July
2011, 37 subjects with a neurodegenerative speech and language disorder were prospectively recruited and underwent detailed
speech and language, neurological, neuropsychological and neuroimaging testing. The neuroimaging battery included 3.0 tesla
volumetric head magnetic resonance imaging, [
18F]-ﬂuorodeoxyglucose and [
11C] Pittsburg compound B positron emission
tomography scanning. Twelve subjects were identiﬁed as having apraxia of speech without any signs of aphasia based on a
comprehensive battery of language tests; hence, none met criteria for primary progressive aphasia. These subjects with primary
progressive apraxia of speech included eight females and four males, with a mean age of onset of 73 years (range: 49–82).
There were no speciﬁc additional shared patterns of neurological or neuropsychological impairment in the subjects with primary
progressive apraxia of speech, but there was individual variability. Some subjects, for example, had mild features of behavioural
change, executive dysfunction, limb apraxia or Parkinsonism. Voxel-based morphometry of grey matter revealed focal atrophy of
superior lateral premotor cortex and supplementary motor area. Voxel-based morphometry of white matter showed volume loss
in these same regions but with extension of loss involving the inferior premotor cortex and body of the corpus callosum. These
same areas of white matter loss were observed with diffusion tensor imaging analysis, which also demonstrated reduced
fractional anisotropy and increased mean diffusivity of the superior longitudinal fasciculus, particularly the premotor
components. Statistical parametric mapping of the [
18F]-ﬂuorodeoxyglucose positron emission tomography scans revealed
focal hypometabolism of superior lateral premotor cortex and supplementary motor area, although there was some variability
across subjects noted with CortexID analysis. [
11C]-Pittsburg compound B positron emission tomography binding was increased
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apraxia of speech. A syndrome characterized by progressive pure apraxia of speech clearly exists, with a neuroanatomic correlate
of superior lateral premotor and supplementary motor atrophy, making this syndrome distinct from primary progressive aphasia.
Keywords: primary progressive apraxia of speech; apraxia of speech; primary progressive aphasia; voxel-based morphometry; dif-
fusion tensor imaging; ﬂuorodeoxyglucose; Pittsburg compound B; supplementary motor area
Abbreviations: AOS = apraxia of speech; PiB = [
11C] Pittsburg compound B; PPA = primary progressive aphasia;
PPAOS = primary progressive apraxia of speech
Introduction
Apraxia of speech (AOS) is a disorder of speech motor planning or
programming that affects the production of speech (Duffy, 2005;
McNeil et al., 2009). Probable synonyms include phonetic disinte-
gration (Alajouanine et al., 1939), cortical dysarthria (Bay, 1962)
and aphemia (Cohen et al., 1993). Among the most common clin-
ical characteristics of AOS are slow rate, articulatory distortions,
distorted sound substitutions and segmentation of syllables in multi-
syllabic words or across words. Articulatory groping and trial and
error articulatory movements are frequently evident. Its original de-
scription and designation as AOS dates back to the 1960s where
the term was coined by Darley to specify a disorder of speech that
was distinguishable from dysarthria and aphasia (Darley, 1967).
AOS is most commonly associated with left hemisphere stroke,
and when stroke induced, there is little if any progression of its
severity and there is often some improvement over time.
In recent years, we and others have documented the occurrence
of AOS in the context of degenerative diseases (Duffy, 2006;
Josephs et al., 2006a; Josephs and Duffy, 2008; Deramecourt
et al., 2010). Unlike in vascular events, AOS in degenerative dis-
eases is characterized by insidious onset that worsens with time,
often culminating in mutism. In degenerative diseases, AOS and
aphasia commonly co-occur. In such circumstances, subjects are
traditionally diagnosed as having primary progressive aphasia
(PPA), in spite of the fact that PPA refers to a disorder of isolated
language impairment (Mesulam, 1982, 2001). In addition, AOS can
be a component of a more widespread degenerative syndrome, for
example, corticobasal syndrome (Bergeron et al., 1996; Boeve
et al., 2003; Josephs and Duffy, 2008). In both of these scenarios,
AOS is typically relegated to ‘accompanying’ symptom status and
its presence and importance is minimized or even ignored. Yet AOS
as the initial presentation of neurodegenerative disease, in the ab-
sence of aphasia or other motor dysfunction, has been reported in
retrospective case reports and case series (Cohen et al., 1993;
Broussolle et al., 1996; Josephs et al., 2005, 2006a; Duffy, 2006;
Ricci et al., 2008; Deramecourt et al., 2010). Unfortunately, the
retrospective nature of these reports has not resulted in general
acceptance that AOS can be the dominant or isolated feature of
neurodegenerative disease.
The limited recognition of AOS in degenerative disease may be
driven by two factors. First, it can be difﬁcult to differentiate AOS
from aphasia. Second, even when recognized, it is usually sub-
sumed under a diagnosis of aphasia, or even dysarthria. Unlike
dysarthria, which is due to disturbance of the neuromuscular
control of speech (Darley et al., 1975), or aphasia which reﬂects
language processing deﬁcits that typically cross language domains
(e.g. semantics, syntax, phonology) and modalities (e.g. spoken
and written language comprehension and expression) and
cannot be attributed to primary motor or sensory deﬁcits (Duffy
and McNeil, 2008), AOS is attributable to impaired planning or
programming of the movements for speech (Wertz et al., 1984),
which results in phonetically and prosodically abnormal speech.
Although AOS and some dysarthria types share some common
features (Box 1), they are distinguishable on the basis of several
characteristics. For example, dysarthrias are not associated with
the distorted sound substitutions or additions, trial and error
Box 1 Features of apraxia of speech
a
1 Slow overall speech rate
b
2 Lengthened intersegment durations (between sounds,
syllables, words or phrases; possibly ﬁlled, including
intrusive schwa)
b
3 Increased sound distortions or distorted sound substitu-
tions with increased utterance length or increased syl-
lable/word articulatory complexity
4 Syllable segmentation within words41 syllable
b
5 Sound distortions
b
6 Syllable segmentation across words in phrases/sentences
b
7 Audible or visible articulatory groping; speech initiation
difﬁculty; false starts/restarts
c
8 Lengthened vowel and/or consonant segments
b
9 Distorted sound substitutions
10 Deliberate, slowly sequenced, segmented, and/or dis-
torted (including distorted substitutions) speech se-
quential motion rates in comparison with speech
alternating motion rates
c
11 Increased sound distortions or distorted sound substitu-
tions with increased speech rate
12 Distorted sound additions (not including intrusive schwa)
13 Sound or syllable repetitions
14 Sound prolongations (beyond lengthened segments)
c
15 Inaccurate (off-target in place or manner) speech AMR’s
(alternating motion rates, as in rapid repetition of ‘puh
puh puh’)
c
16 Reduced words per speech breath group relative to
maximum vowel duration
a Features are ordered from most to least prevalent among the subjects in this
study. Features 1-5 were present in all 12 subjects. All features were present in
at least one subject. Note that both prosodic and articulatory abnormalities are
captured in several of the listed features.
b Can also be present in spastic dysarthria (only two subjects had unequivocal
spastic dysarthria).
c Can also be present in aphasia, but none of the 12 subjects were otherwise
aphasic.
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complexity or rate that are common in AOS, and AOS is not
associated with the strained or hypophonic voice quality, reduced
loudness, hypernasality, or rapid/accelerated rate that occur in
some dysarthria types, including those that are relevant to this
study (spastic and hypokinetic).
AOS is sometimes mistaken as aphasia, especially when phon-
etic (motor) errors secondary to abnormal motor planning are
misconstrued as phonological (linguistic or phonemic) errors.
Phonological errors, however, typically do not result in distorted
sound production and often occur within utterances that are
normal in rate and prosody. It is therefore possible to separate
AOS from aphasia, and plausible to predict the existence of a
neurodegenerative syndrome in which AOS is the sole or domin-
ant feature.
The aim of this study was to document that AOS, in the ab-
sence of aphasia or obvious signs of a prominent motor disorder
such as corticobasal syndrome, can be the presenting manifest-
ation of neurodegenerative disease, a clinical presentation we will
refer to as primary progressive AOS, or primary progressive
apraxia of speech (PPAOS) (Duffy and McNeil, 2008). In addition,
we aimed to assess commonalities and variability in the neuro-
logical, neurobehavioural, neuropsychological and neuroimaging
characteristics of individuals with this syndrome.
Patients and methods
Recruitment
Between 1 July 2010 and 31 July 2011 we recruited all patients who
presented to the Department of Neurology with a speech and lan-
guage disorder suspected to be secondary to a degenerative process.
Only subjects over the age of 18, with an informant to provide inde-
pendent evaluation of functioning, and who spoke English as their
primary language, were included. All subjects underwent detailed
speech and language examination, neurological evaluation, neuropsy-
chological testing and neuroimaging analysis over a span of 48–72h.
Clinical diagnosis of PPAOS was rendered based solely on data from
speech and language assessments without any reference to neuro-
logical, neuropsychological or neuroimaging results at a consensus
meeting held 1–2 months after enrolment. All subjects had video
and audio recordings of their entire comprehensive, formal speech
and language assessment, as well as general conversation and per-
formance on a measure of oral praxis.
Diagnosis was made according to operational deﬁnitions, after
review of the video and audio recordings and review of speech and
language test scores as described below. In order to be included in this
study all subjects must have been diagnosed with PPAOS; any evi-
dence suggesting aphasia could not be more than equivocal.
Dysarthria could be present. Therefore, any subject with even mild
(but unequivocal) evidence of aphasia was excluded. Subjects with
concurrent illnesses that could account for the speech deﬁcits, such
as traumatic brain injury, stroke or developmental syndromes, and
subjects meeting criteria for another neurodegenerative disease, such
as Alzheimer’s type dementia (McKhann et al., 1984), dementia with
Lewy bodies (McKeith et al., 2005), behavioural variant frontotem-
poral dementia (Neary et al., 1998), probable progressive supranuclear
palsy (Litvan et al., 1996), corticobasal syndrome (Boeve et al., 2003),
multiple system atrophy (Gilman et al., 2008), or motor neuron de-
generation (Brooks et al., 2000) were excluded. Subjects were also
excluded if MRI was contraindicated (metal in head, cardiac pace
maker, etc.), if there was severe claustrophobia or conditions that
might confound brain imaging studies (e.g. structural abnormalities,
including subdural haematoma or intracranial neoplasm), or if they
were medically unstable or were on medications that might affect
brain structure or metabolism, (e.g. chemotherapy).
During this period, 40 subjects were screened of which 37 were
recruited and three excluded (Supplementary Fig. 1). One subject
was excluded due to a tiny chronic lacunar infarct in the left centrum
semiovale and left subinsular white matter, one as a result of having a
pacemaker, and one who was determined to meet clinical criteria for
Alzheimer’s disease (McKhann et al., 1984).
The study was approved by the Mayo Clinic institutional review
board and all subjects consented for enrolment into the study.
Speech and language assessment
The Western Aphasia Battery-revised Part 1 (Kertesz, 2007) served as
the primary measure of global language ability; the Writing Output
subtest from Part 2 of the Western Aphasia Battery served as a
speech-independent measure of language expression. A 22-item ver-
sion of Part V of DeRenzi and Vignolo’s Token Test (DeRenzi and
Vignolo, 1962) served as a challenging measure of verbal comprehen-
sion ability (Wertz et al., 1971), and the 15-item Boston Naming Test
(Lansing et al., 1999) as a sensitive measure of confrontation-naming
ability. Action (verb) Fluency (Woods et al., 2005) and Letter (FAS)
Fluency (Loonstra et al., 2001) tasks served as indices of rapid-word
retrieval ability for those categories. A score 42 standard deviations
(SD) below the mean on all language tests with published or derived
mean and standard deviation was considered abnormal.
Judgements about motor speech abilities were based on all spoken
language tasks of the Western Aphasia Battery plus additional speech
tasks that included vowel prolongation, speech alternating motion
rates (e.g. rapid repetition of ‘puhpuhpuh...’), speech sequential
motion rates (e.g. rapid repetition of ‘puhtuhkuh’), word and sentence
repetition tasks and a conversational speech sample. Sixteen speech
characteristics (Box 1), consistent with current criteria for AOS diag-
nosis (Duffy, 2005; Wambaugh et al., 2006; McNeil et al., 2009), or
observations of characteristics of AOS associated with neurodegenera-
tive disease (Duffy, 2006), and selected to cast a wide net for captur-
ing features of the disorder, were rated on an AOS rating scale, which
provided a description of AOS characteristics and their prominence.
Ratings were based on the following scale: 0 = not present; 1 = detect-
able but not frequent; 2 = frequent but not pervasive; 3 = nearly
always evident but not marked in severity; 4 = nearly always evident
and marked in severity. Normal cut-off values for the summed ratings
were based on the performance of 14 subjects with PPA for whom
there was no clinical evidence of AOS. A global AOS severity rating
(0–4) was also made.
The same speech tasks were also judged for the presence or absence
of dysarthria, which was rated on a 0–4 severity scale. An eight-item
measure of non-verbal oral praxis, with responses to each item rated
on a 0–4 scale (with a score of 4 representing best/normal perform-
ance), served as a quantitative index of non-verbal oral apraxia.
A global judgement about the presence or absence of non-verbal
oral apraxia was also made.
Quantitative scores and video recordings of crucial aspects of the
test protocol were reviewed for all subjects by two authors (J.R.D. and
E.A.S.) who made independent judgements about the presence or
absence of aphasia, AOS, dysarthria and non-verbal oral apraxia,
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presence or absence of aphasia and presence or absence of AOS and
non-verbal oral apraxia was achieved for 11/12 subjects. Discussion
regarding the presence or absence of AOS was required for consensus
for Subject 8, whose AOS was very mild and the least severe among
the 12 subjects. Independent agreement regarding the presence or
absence of dysarthria was 100%. Both judges agreed after discussion
that the evidence for spastic dysarthria was equivocal for Subjects 1
and 3, and that evidence of a hypokinetic component for Subject 7
was equivocal.
Neurological examination
All subjects underwent detailed neurological examination by a behav-
ioural and movement disorders specialist (K.A.J.), as well as standar-
dized testing of cognitive, behavioural, functional and motor
performance. Testing of general cognitive function included the
Mini-Mental State Examination (Folstein et al., 1975) and the
Montreal Cognitive Assessment battery (Nasreddine et al., 2005); as-
sessment of executive function with the Frontal Assessment Battery
(Dubois et al., 2000); assessment of praxis with the Limb Apraxia
subscale of the Western Aphasia Battery (Kertesz, 2007); assessment
of calculation with the calculation subtest of the Montreal Cognitive
Assessment battery (Nasreddine et al., 2005); assessment of facial
recognition was performed by asking the subject to select the one
famous face from a panel of three similar looking faces, for a total
of 10 different panels (norms determined on 50 cognitively normal
subjects); assessment of functional performance with the Clinical
Dementia Rating Scale (Hughes et al., 1982); degree of behavioural
dysfunction with the Frontal Behavioural Inventory (Kertesz et al.,
1997); assessment of neuropsychiatric features with the brief question-
naire form of the Neuropsychiatric Inventory (Kaufer et al., 2000);
assessment of motor function with the Movement Disorders Society
sponsored revision of the Uniﬁed Parkinson’s Disease Rating Scale Part
III (Goetz et al., 2008); assessment of eye movement abnormality with
the Progressive Supranuclear Palsy Saccadic Impairment Scale
(Whitwell et al., 2011b); and documentation of the presence or ab-
sence of limb myoclonus, dystonia and falls. A Z-score of 42S D
below the mean on all tests with published or derived mean and
standard deviation was considered abnormal.
Neuropsychological testing
All neuropsychological tests were administered by a trained psychom-
etrist. A clinical neuropsychologist (M.M.M.) oversaw test administra-
tion, scoring accuracy and quality control. The Wide Range
Achievement Test 3rd edition (Wilkinson, 1993), along with educa-
tional and occupational background, was used to estimate premorbid
ability level.
Test of motor speed included Trail Making Test A (Spreen and
Strauss, 1998); tests of executive function included Trail Making Test
B (Spreen and Strauss, 1998) and the Delis–Kaplan Executive Function
System Card Sort (Delis et al., 2001); tests of learning and memory
included the Auditory Verbal Learning Test (Rey, 1964) and the
Logical Memory and Visual Reproduction subtests from the Wechsler
Memory Scale-III (Wechsler, 1987), and tests of visuospatial and
visuo-perceptual function included Cube Analysis and Incomplete
Letters, respectively, from the Visual Object and Space Perception
Battery (Warrington and James, 1991), as well as the Rey–Osterreith
Complex Figure Test (Osterrieth, 1944; Rey, 1964) for more complex
visuospatial and visuoconstructional testing. Mayo Older American
Normative Studies age-adjusted scaled scores (Ivnik et al., 1992)
were used for all neuropsychological variables except for the Delis–
Kaplan Executive Function System Sorting Test, Wide Range
Achievement Test and Cube Analysis and Fragmented Letters for
which published norms were used. The Wide Range Achievement
Test Reading score is expressed as a standard score with a mean of
100 and a SD of 15. The Mayo Older American Normative Studies
age-adjusted scaled scores and Sorting test scores are constructed to
have a mean of 10 and SD of 3 in cognitively healthy participants.
Scores below 7 are generally considered abnormal. The Cube analysis
and Fragmented Letters were converted to Z-scores. A Z-score of 42
SD below the mean on the Visual Object and Space Perception Battery
subtests was considered abnormal.
Neuroimaging
Control subjects
All subjects with PPAOS were matched by age and gender to a cohort
of healthy control subjects at a subject:control ratio of 1:2. All subjects
and controls had identical imaging sequences, including volumetric
head MRI, diffusion tensor imaging, [18F]-ﬂuorodeoxyglucose PET
and [
11C] Pittsburg compound B (PiB) scanning.
Magnetic resonance and positron emission tomography
image acquisition
All subjects underwent a standardized MRI imaging protocol at 3.0 T,
which included a 3D magnetization prepared rapid acquisition gradient
echo sequence (repetition time/echo time/T1 = 2300/3/900ms; ﬂip
angle 8, 26-cm ﬁeld of view; 256  256 in-plane matrix with a
phase ﬁeld of view of 0.94, slice thickness of 1.2mm, in-plane reso-
lution 1) and a single-shot echo-planar diffusion tensor imaging pulse
sequence (repetition time = 10200ms; in-plane matrix 128/128;
in-plane resolution 2.7, ﬁeld 35cm; phase ﬁeld of view 0.66; 42 dif-
fusion encoding steps and four non-diffusion weighted T2 images;
2.7mm isotropic resolution). Parallel imaging with a sensitivity encod-
ing factor of 2 was used for the diffusion tensor imaging acquisition.
All PET scans were acquired using a PET/CT scanner (GE Healthcare)
operating in 3D mode. For ﬂuorodeoxyglucose-PET, subjects were
injected with ﬂuorodeoxyglucose (average, 459 MBq; range, 367–
576 MBq) in a dimly lit room with minimal auditory stimulation.
After a 30-min uptake period an 8-min ﬂuorodeoxyglucose scan was
performed consisting of four 2-min dynamic frames following a low
dose CT transmission scan. For PiB-PET, subjects were injected with
PiB (average, 614 MBq; range, 414–695 MBq) and after a 40–60-min
uptake period a 20min PiB scan was obtained consisting of four 5-min
dynamic frames following a low dose CT transmission scan. Standard
corrections were applied. Individual frames of the ﬂuorodeoxyglucose
and PiB dynamic series were realigned if motion was detected and
then a mean image was created. Emission data were reconstructed
into a 256  256 matrix with a 30-cm ﬁeld of view. The image
thickness was 3.75mm.
Voxel-based morphometry
All magnetization prepared rapid acquisition gradient echo images
underwent pre-processing correction for gradient non-linearity (Sled
et al., 1998) and intensity non-uniformity (Jovicich et al., 2006).
Voxel-based morphometry (Ashburner and Friston, 2000) using
SPM5 was utilized to assess patterns of grey and white matter
volume loss in subjects with PPAOS compared with controls.
All magnetization prepared rapid acquisition gradient echo scans
were normalized to a customized template and segmented using uni-
ﬁed segmentation (Ashburner and Friston, 2005), followed by a
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and white matter images were modulated and smoothed at 8mm
full-width at half-maximum. Two-sided t-tests were used to assess
patterns of loss in the subjects with PPAOS compared with controls.
Results did not survive family-wise error correction for multiple com-
parisons, and hence were assessed uncorrected at P50.001.
Since asymmetric grey matter patterns were observed (see ‘Results’
section) we calculated an asymmetry score for the lateral premotor
cortex and supplementary motor area for each subject [(left volume
 right volume)*2/left volume plus right volume]. Left and right
supplementary motor area volume was generated using
atlas-based parcellation and the automatic anatomical labelling atlas
(Tzourio-Mazoyer et al., 2002), as previously described (Whitwell
et al., 2009). Left and right lateral premotor cortex volume was gen-
erated by placing a 20-mm diameter sphere over the peak voxel in this
region (left: 25, 3, 51, right: 25, 3, 51) and multiplying by the
grey matter probability masks.
Diffusion tensor imaging analysis
Each of the 42 diffusion-weighted images was registered to the
non-diffusion-weighted b0 images using afﬁne transformations.
Images were brain-extracted (Smith et al., 2004) and fractional anisot-
ropy and mean diffusivity maps were generated (Behrens et al., 2003).
A 2-compartment partial volume correction was performed on both
the fractional anisotropy and mean diffusivity images. Voxel-wise stat-
istical analysis of the fractional anisotropy data was performed using
tract-based spatial statistics (Smith et al., 2006) (http://www.fmrib.ox.
ac.uk/fsl). The fractional anisotropy and mean diffusivity images for
each subject were aligned into common space using a non-linear regis-
tration, and then afﬁnely transformed into Montreal Neurological
Institute space. A mean fractional anisotropy image was created
from all subjects, and was thinned to create a mean fractional anisot-
ropy skeleton that represents the centres of all tracts common to the
group. The fractional anisotropy skeleton was thresholded at 40.25 to
exclude peripheral tracts with intersubject variability and partial volume
effects. Each subject’s aligned fractional anisotropy and mean diffusiv-
ity data were then projected onto this skeleton and the resulting data
were fed into voxel-wise cross-group statistics. Since results did not
survive family-wise error correction, all results were assessed
uncorrected at P50.05.
Fluorodeoxyglucose-positron emission tomography
analysis
The ﬂuorodeoxyglucose-PET images were analysed both at the
individual-level and at the group-level.
In order to assess individual-level patterns of hypometabolism we
used the clinical tool of 3D stereotactic surface projections (Minoshima
et al., 1995). This is a fully automated analysis. All scans were re-
aligned and spatially normalized and underwent non-linear warping.
The scans were sampled at 16 000 predeﬁned cortical locations and
projected on a 3D image. The activity in each subject’s PET data set
was normalized to the pons and compared with an age-segmented
normative database, yielding a 3D stereotactic surface projections
Z-score image. The image produced by this analysis produces a meta-
bolic map using the Z-scores as calculated for each surface pixel. The
software packages used to perform these analyses included CortexID
(GE Healthcare).
Group-level ﬂuorodeoxyglucose-PET analysis was performed with
SPM5. For each subject, all voxels in the ﬂuorodeoxyglucose-PET
image were divided by the median ﬂuorodeoxyglucose uptake of the
pons to form uptake ratio images. The uptake ratio images were
co-registered to the magnetization prepared rapid acquisition gradient
echo image for each subject using six degrees of freedom afﬁne regis-
tration. Each magnetization prepared rapid acquisition gradient echo
image was normalized and segmented and the grey and white matter
segmentations saved in native space, and then combined to form a
brain tissue probability mask. The masks were re-sampled to the
resolution of the PET images, smoothed at 6mm full-width at
half-maximum, and used to perform a 2-compartment partial
volume correction (Meltzer et al., 1999). The original uptake ratio
images, and the partial volume correction uptake images, were then
normalized to the customized template using the normalization
parameters created from normalizing the magnetization prepared
rapid acquisition gradient echo image. All images were smoothed at
8mm full-width at half-maximum. Two-sided t-tests were used to
assess voxel-wise patterns of ﬂuorodeoxyglucose hypometabolism
in the subjects with PPAOS compared with controls using both the
partial volume correction and non-partial volume correction images.
Results were assessed uncorrected at P50.001 and after correction
for multiple comparisons using the family-wise error correction at
P50.05.
Pittsburgh compound B positron emission tomography
For each subject, all voxels in the PiB-PET image were divided by the
median PiB uptake of the cerebellum to form uptake ratio images. The
uptake ratio images were co-registered to the magnetization prepared
rapid acquisition gradient echo images for each subject using six de-
grees of freedom afﬁne registration. A 2-compartment partial volume
correction (Meltzer et al., 1999) was performed as described above for
the ﬂuorodeoxyglucose-PET analysis. The automated anatomical label-
ling atlas was transformed into native space and used to calculate
median PiB uptake for the following six regions of interest: temporal
lobe, parietal lobe, posterior cingulate/precuneus, anterior cingulate,
prefrontal cortex and occipital lobe (left and right were combined
for all regions). PiB uptake values for each subject with PPAOS were
converted into Z-scores reﬂecting how many standard deviations each
subjects PiB uptake values were above the mean of the control group.
We considered PiB binding to be increased in the subjects with PPAOS
if the Z-scores 52 in all six regions, in a similar manner to previously
described (Okello et al., 2009).
Results
Subjects
Twelve subjects met inclusion and exclusion criteria for PPAOS
(Table 1 and Supplementary Fig. 1). All 12 presented with the
insidious onset and progression of speech difﬁculties. Chief com-
plaints included, for example, ‘I can’t get my words out’ or
‘I stumble over my words’. The majority were female (8/12) and
all but two subjects were right-handed. All subjects had completed
at least a high school level education (12 years) and all but three
had completed some college level education. The majority of sub-
jects had had speech symptoms for 43 years, but ﬁve had speech
symptoms that were present for 54 years. The median age of
onset of the cohort was 73 years with only three subjects having
symptom onset before 65 years of age. None of the subjects had a
family history of any neurological diseases.
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Speech–language ﬁndings are summarized in Table 1. All subjects
scored within the normal range on the Western Aphasia Battery,
with Aphasia Quotients 594.1 for all subjects. All of the compo-
nent scores that contribute to the overall Aphasia Quotients (i.e.
spontaneous speech score, auditory verbal comprehension score,
repetition score, naming and word-ﬁnding score) were also
normal. Western Aphasia Battery writing output scores were at
or near the maximum score for all subjects, except Subject 6
whose reduced score on that time limited task was attributable
to slowed motoric execution, as opposed to any language deﬁ-
ciencies. This subject also had the worst performance on the Trail
Making Test A, as reported below.
Performances on the Token test were all within 2 SD of the
norm. Eight subjects had abnormal Action Fluency scores and six
had abnormal Letter Fluency scores. This stands in contrast to the
normal naming performance of all subjects on the Boston Naming
Test and naming subtest of the Western Aphasia Battery.
All 12 subjects had abnormal total scores on the quantitative
total score index of the AOS rating scale. For all 12 subjects,
100% had speech abnormalities on ﬁve items of the AOS rating
scale (Box 1) and 75% had speech abnormalities on four add-
itional items. Clinically judged severity of AOS ranged from very
mild to moderate. Although AOS and dysarthria have some over-
lapping features, the four subjects with PPAOS with possible or
deﬁnite mild dysarthria (Subjects 1, 3, 6 and 7), each had four to
seven features of AOS that are not associated with dysarthria.
There was no evidence of dysarthria for 8/12 subjects. Two had
mild spastic dysarthria and two had equivocal evidence of spastic
dysarthria. One subject with spastic dysarthria was judged to pos-
sibly also have a hypokinetic component. In none of the subjects
with dysarthria was the dysarthria judged as more severe than
the AOS.
Six of the 12 subjects were judged to have a non-verbal oral
apraxia; three mild, two moderate and one severe.
Neurological ﬁndings
There were no speciﬁc, consistently shared patterns of impairment
on any of the neurological measures among the subjects with
PPAOS, although there was some individual variability (Table 2).
Table 1 Summary of demographics and primary speech-language ﬁndings
Subjects Median (range)
12 34 5 6 78 9 1 0 1 1 1 2
Demographics
Gender F F F F M F M M M F F F F:M (8:4)
Handedness R R Amb R R R R R L R R R R:L (10:1)
Education 14 15 15 14 12 15 16 16 20 12 12 15 15.0 (12–20)
Illness duration 1.5 3.0 6.0 4.3 4.8 4.0 4.8 2.5 3.0 1.4 2.0 1.5 3.0 (1.4–6.0)
Age at onset 82 76 74 67 49 71 74 60 62 78 67 74 72.5 (49–82)
Speech and Language
WAB
Aphasia Quotient (/100) 96 100 94.1 96 96.6 97.8 96.7 99.8 97.4 97 95.6 98.7 96.9(95.6–100)
Spontaneous Speech (/20) 19 20 19 20 19 20 19 20 19 20 20 20 20(19–20)
Aud. Verbal Comp (/10) 9.6 10 9.65 9.95 10 10 10 9.8 10 9.8 9.8 9.95 9.95(9.6–10)
Repetition (10) 9.8 10 9.2 9.2 9.3 9.4 9.9 9.4 9.7 9.4 9 9.8 9.4 (9.2–10)
Naming/Word Finding (/10) 9.6 10 9.2 9.8 10 9.5 9.5 9.9 10 9.3 9 9.6 9.6(9.2–10)
WAB Writing Output (/34) 34 33.5 34 31 33 23.5
a 32 34 34 34 33 34 34(23.5–34)
Token Test Part V (/22) 21 22 19 19 22 21 19 21 20 19 16 22 20.5(16–22)
Action Fluency 20 12 12 13 16 51 01 1 15 13 16 11 12.5 (10–20)
Letter Fluency 42 28 32 34 11 8 23 33 24 34 15 15 26(8–42)
Boston Naming Test (/15) 15 15 15 15 12 13 14 15 15 14 13 14 14.5(12–15)
Apraxia of Speech (+/–) + ++ ++++ +++++
AOS rating scale total score
(/64; 0 = best)
19 12 20 12 20 18 33 9 11 25 16 16 17(9–33)
Number of abnormal
features (/16)
10 8 13 12 14 10 15 9 11 13 10 9 10.5(8–15)
Severity (0–4) 2 12 1212 0 . 5 12111(1–2)
Dysarthria None
b None None
b None None SP SP
c None None None None None
Severity (0–4) 1 0 1 0 0 1 1 000000(0–1)
NVOA score (/32; 32 = normal) 27 29 28 32 24 19 9 32 32 32 32 32 30.5(9–32)
NVOA Mild Mild Mild None Mod Mod Severe None None None None None
Bold values represent abnormal values in reference to normative data (2 SD below mean).
F = female; L = left; M = male; Mod = moderate; NVOA = none verbal oral apraxia; R = right; SP = spastic; WAB = Western aphasia battery.
a Score reduced secondary to motor slowness on a timed test.
b The presence of spastic dysarthria was equivocal.
c Hypokinetic dysarthria was equivocal.
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global cognitive function. Five subjects (Subjects 1, 3, 6, 7 and 11)
performed outside the range of normal on testing of executive
function with the Frontal Assessment Battery. Only one subject
performed below average on calculation (Subject 9). All subjects
performed within the normal range on the test of facial recogni-
tion. Four subjects (Subjects 3, 6, 7 and 10) showed mild–moder-
ate impairment on praxis assessment; in all four, poor performance
was driven mainly by difﬁculties with the complex items, for ex-
ample, ‘pretend to start and drive a car’.
Only one subject (Subject 7) had mild functional impairment as
measured by the Clinical Dementia Rating Scale sum of boxes.
Three subjects were impaired on neurobehavioural testing
(Subjects 5, 7 and 11); all three on the Neuropsychiatry
Inventory, but only two on the Frontal Behavioural Inventory
(Subjects 5 and 7).
Three subjects (Subjects 2, 3 and 6) had mild–moderate general-
ized motor dysfunction as measured by the Uniﬁed Parkinson’s
Disease Rating Scale Part III. One of these subjects (Subject 3)
also had evidence of mild up and down gaze impairment as mea-
sured by the progressive supranuclear palsy Saccadic Impairment
Scale. This subject had been followed clinically for many years
with AOS prior to enrolment and had a disease duration of 6
years at the time of enrolment into the study; she had isolated
motor speech impairment for 5.5 years, only developing eye
movement difﬁculties within the previous 6 months. None of the
subjects with PPAOS had dystonia, myoclonus or falls.
Neuropsychological ﬁndings
There were no consistently shared patterns of impairment across
subjects on any of the neuropsychological tests. Similar to
the neurological ﬁndings, there was some individual variability
(Table 3). Three subjects were below average on tests of executive
function; Subjects 3 and 11 were severely impaired on Trail
Making Test B, and Subject 12 was mildly impaired on Delis–
Kaplan Executive Function System Card Sort Sorting. Subject 11
also performed poorly on Trail Making Test A, a test of speed and
motor processing, as did Subject 6. Subject 5 had evidence of
mildly impaired learning, and only Subjects 5 and 10 of mild
memory impairment, as measured by the Auditory Verbal
Learning Test and Wechsler Memory Scale-III Visual
Reproduction subtest. Performances on the Wechsler Memory
Scale-III Logical Memory subtest were all within the normal
range. No subject performed 42 SD below the mean on any
tests of visuospatial or perceptual function.
Neuroimaging
For all imaging group analyses, the 12 subjects with PPAOS were
compared with 24 normal controls, of which eight (33%) were
male. At the time of scan the median (range) age of the 12 sub-
jects with PPAOS was 75.3 years (53.9–84.2) and the 24 controls
was 75.0 years (59.6–84.2). The median time from onset to time
of scan in the subjects with PPAOS was 3.0 years (1.4–6.0).
Table 2 Summary of neurological data
Tests Subjects Median
(Range)
1234567 891 0 1 1 1 2
MMSE (/30) 30 30 28 30 27 29 27 30 30 30 29 29 29.5 (27–30)
MOCA (/30) 28 30 25 28 25 28 26 28 27 29 29 28 28.0 (25–30)
FAB (/18) 15 17 14 16 16 15 15 18 16 18 15 17 16.0 (6–18)
Apraxia (/60) 59 59 51 58 59 48 49 60 60 49 58 57 58.0 (48–60)
Calculation (/3) 3 3 3 3 3 3 3 3 2 3 3 3 3.0 (2–3)
Faces (/10) 10 10 10 10 10 10 9 10 10 10 10 8 10.0 (8–10)
CRD SOB (/18; 0 = best) 0 0 0 0 0 0 1.5 0 0 0 0 0 0 (0–2)
FBI (/72; 0 = best) 2 4 8 2 25 5 15 8 2 4 6 3 4.5 (3–25)
UPDRS (/132; 0 = best) 9 24 25 85 33 13 5 8 5 4 6 8.0 (4–33)
PSIS (/5; 0 = best) 0 1 3 0 0 0 1 0 0 0 0 1 0.0 (0–1)
NPI Total (/36; 0 = best) 1 2 0 0 9 0 5 3006 1 1.0 (0–9)
Delusions 0 0 0 0 0 0 0 0 0 0 0 0 0.0 (0–0)
Hallucinations 0 0 0 0 0 0 0 0 0 0 0 0 0.0 (0–0)
Agitation 0 0 0 0 2 0 0 0 0 0 1 0 0.0 (0–2)
Depression 0 1 0 0 0 0 0 0 0 0 2 1 0.0 (0–2)
Anxiety 1 0 0 0 0 0 1 0 0 0 1 0 0.0 (0–1)
Euphoria 0 0 0 0 0 0 0 0 0 0 0 0 0.0 (0–0)
Apathy 0 1 0 0 3 0 22 0 0 1 0 0.0 (0–2)
Disinhibition 0 0 0 0 0 0 0 0 0 0 0 0 0.0 (0–0)
Irritability 0 0 0 0 3 0 2 1 0 0 1 0 0.0 (0–3)
Motor disturbance 0 0 0 0 0 0 0 0 0 0 0 0 0.0 (0–0)
Night behaviours 0 0 0 0 1 0 0 0 0 0 0 0 0.0 (0–1)
Appetite/Eating 0 0 0 0 0 0 0 0 0 0 0 0 0.0 (0–0)
Values in bold represent values that are considered abnormal.
CDR SOB = Clinical Dementia Rating Scale Sum of Boxes; FAB = Frontal Assessment Battery; FBI = Frontal Behavioural Inventory; MMSE = Mini-mental State Examination;
MOCA = Montreal Cognitive Assessment; ND = not done; NPI = Neuropsychiatric Inventory; PSIS = Progressive Supranuclear Palsy Saccadic Impairment Scale.
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Grey and white matter volume loss was observed bilaterally in the
premotor cortex, particularly involving the supplementary motor
area, in subjects with PPAOS compared with controls (Fig. 1A and
B). Grey matter loss in the lateral premotor cortex was only
observed in the left hemisphere and was restricted to the superior
premotor cortex, whereas white matter loss was observed bilat-
erally in both superior and inferior premotor cortex. The absolute
grey matter asymmetry score in both the supplementary motor
area and lateral premotor cortex in the PPAOS group were 0.09
(range: 0.01–0.18) and 0.03 (range: 0.01–0.15), respectively,
and did not differ from controls [0.07 (0.00–0.14) and 0.03
(0.00–0.14)]. However, ﬁve subjects with PPAOS had a lateral
premotor asymmetry score greater than the control mean, and
all ﬁve showed greater involvement of the left hemisphere.
Seven subjects with PPAOS had a supplementary motor area
asymmetry score greater than the control mean, with six showing
greater involvement of the left and one showing greater involve-
ment of the right. An additional region of white matter loss was
observed in the body of the corpus callosum.
Diffusion tensor imaging analysis
Reduced fractional anisotropy was observed bilaterally in the body
of corpus callosum, and superior longitudinal fasciculus, including
the left anterior superior longitudinal fasciculus as it descends
through the external capsule, in subjects with PPAOS compared
with controls (Fig. 2). Increased mean diffusivity was observed in
the same regions in PPAOS, although the spatial extent of the
ﬁndings was less. No regions showed reduced fractional anisotropy
in the opposite comparison, i.e. in controls compared with subjects
with PPAOS, or increased mean diffusivity in controls compared
with PPAOS.
Fluorodeoxyglucose positron emission tomography
analysis
The ﬂuorodeoxyglucose-PET 3D stereotactic surface projections
images for each subject with PPAOS are shown in Fig. 3. The
degree of hypometabolism was variable across subjects; although,
when present, most often involved the supplementary motor
area (Subjects 2 and 6–11) and lateral frontal lobe (Subjects 2, 3
and 6–11). Patterns of hypometabolism in these regions appeared
asymmetric in some subjects, with greater involvement of the left
in Subjects 6, 8, 9 and 10, and greater involvement of the right in
Subjects 2 and 11. Only Subjects 9 and 11 showed additional
involvement of the temporal lobe (left posterior temporal in
Subject 9 and right temporoparietal in Subject 11). Subjects 7,
8, 9 and 11 showed hypometabolism in the precuneus.
In the non-partial volume corrected group-level analysis,
ﬂuorodeoxyglucose-PET hypometabolism was observed bilaterally
in superior lateral premotor cortex, particularly involving supple-
mentary motor area, in subjects with PPAOS compared with con-
trols (Fig. 1C). Regions of hypometabolism in the left superior
lateral premotor cortex and supplementary motor area survived
correction for multiple comparisons. After partial volume correc-
tion, only small voxels of hypometabolism remained in left super-
ior lateral premotor cortex and supplementary motor area in the
subjects with PPAOS compared with controls.
Table 3 Summary of Neuropsychological data
Tests Subjects Median (range)
1234567891 0 1 1 1 2
WRAT Reading 113 117 102 99 83 104 97 107 118 97 108 101 103 (97 to 118)
AVLT-LOT 14 18 17 14 5 10 10 11 10 12 11 9 11.0 (5 to 18)
AVLT_TrialB 12 10 10 12 7 9 7 10 11 7 9 11 10.0 (7 to 12)
AVLT Trial6 11 15 14 13 2 10 10 9 9 10 9 11 10.0 (2 to 15)
AVLT_DelayRecall 14 18 16 13 5 10 12 10 8 11 11 11 11.0 (5 to 18)
AVLT % Retention 11 15 14 13 5 10 13 12 8 10 15 15 12.5 (5 to 15)
AVLT_Recognition 13 12 13 13 7 13 10 10 9 10 13 9 12.5 (7 to 15)
WMS-LM I 9 ND 11 11 ND 10 11 8 14 12 13 14 11.0 (8 to 14)
WMS-LM II 10 ND 12 13 ND 11 13 10 15 12 13 15 12.5 (10 to 15)
WMS-LM PR 11 ND 12 13 ND 13 14 10 16 11 13 13 13.0 (10 to 16)
WMS-VR I 12 11 11 9 4 15 11 15 15 8 8 14 11.0 (4 to 15)
WMS-VR II 12 15 12 14 9 11 15 14 18 6 12 15 13.0 (6 to 18)
WMS-VR PR 11 16 12 17 13 10 15 13 18 6 14 14 13.5 (6 to 18)
Trail Making Test A 10 8 9 8 15 4 9 7 15 9 5 9 9.0 (5 to 15)
Trail Making Test B 14 10 d/c 7 11 7 11 8 13 10 2 10 10.0 (dc to 14)
DKEFS Sorting 10 13 9 12 8 12 10 9 18 11 12 5 10.5 (5 to 18)
Rey-O Drawing 8 7 7 10 10 10 7 12 10 12 9 11 10.0 (7 to 12)
VOSP Letters Raw (/20) 20 20 20 18 20 18 20 20 20 20 19 20 20.0 (18 to 20)
VOSP Letters Z-score 0.64 0.64 0.64 0.82 0.74 0.82 0.64 0.74 0.74 0.64 0.63 0.64 0.6 (0.8 to 0.74)
VOSP Cube Raw (/10) 10 10 5 9 8 10 5 10 10 10 9 10 10.0 (5 to 10)
VOSP Cube Z-score 0.71 0.71 1.73 0.22 1.00 0.71 1.73 0.58 0.58 0.71 0.68 0.71 0.6 (1.9 to 0.71)
Bold represent values that considered at least mildly abnormal.
AVLT = Auditory Verbal Learning Test; DKEFS = Delis-Kaplan Executive Function System; LM = logical memory; LOT = Learning over trials; VOSP = Visual Object and
Space Perception; VR = Visual Reproduction; d/c = discontinued; PR = percent retention; WMS = Wechsler Memory Scale; WRAT = Wide Range Achievement Test.
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Figure 4A shows the PiB retention Z-scores for each of the six
regions for each subject with PPAOS. Only one subject (Subject
2) showed increased PiB retention across any of the six regions.
The PiB retention image for this subject is shown in Fig. 4B
demonstrating increased PiB retention across all six regions. The
remaining 11 subjects with PPAOS showed low PiB retention
values across all six regions.
Discussion
In this study, we describe the clinical and imaging features of
12 subjects with a progressive neurological disorder dominated
Figure 2 Results of the tract-based spatial statistics analysis of fractional anisotropy. The mean fractional anisotropy skeleton is shown in
green with red showing regions of reduced fractional anisotropy in subjects with PPAOS compared with controls. Results are shown
uncorrected for multiple comparisons at P50.05. L = left; R = right.
Figure 1 Three dimensional surface renderings showing regions of grey matter volume loss (A, red), white matter volume loss (B, green)
and ﬂuorodeoxyglucose-PET hypometabolism (C, blue) in the subjects with PPAOS compared with controls. Results are shown uncor-
rected for multiple comparisons at P50.001.
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signs. We refer to these subjects as having PPAOS.
Mesulam (1982) ﬁrst described a series of patients with a pro-
gressive loss of language function which he later referred to as
PPA (Mesulam, 1987). The diagnosis of PPA requires that for at
least the ﬁrst 2 years the most prominent clinical feature must be
difﬁculty with language (Mesulam, 2003). Importantly, PPA
should not include syndromes characterized by ‘pure progressive
dysarthria or disruption of the formation of words rather than
their use’ (Mesulam, 2003), i.e. AOS. Recently, a consensus
panel of experts published a manuscript further dividing PPA
into different variants based on the pattern of impaired language
(Gorno-Tempini et al., 2011). Three subtypes were recognized: a
non-ﬂuent/agrammatic variant that can include AOS; a semantic
variant; and a logopenic variant. In order to receive a diagnosis of
one of these three variants, however, the subject must ﬁrst meet
criteria for PPA. The 12 subjects reported in this manuscript all had
preserved language function and, therefore, did not meet criteria
for a diagnosis of PPA. The below average performance on action
and letter ﬂuency measures alone are insufﬁcient to diagnose
aphasia.
Some researchers have suggested that subjects with AOS should
be considered no different from subjects with the non-ﬂuent/
agrammatic variant of PPA (Knibb et al., 2009). However, subjects
with the non-ﬂuent agrammatic variant of PPA must be aphasic
and speciﬁcally exhibit agrammatism in verbal and/or written
form. Subjects with this PPA variant typically perform poorly on
the Western Aphasia Battery ﬂuency measure (Gorno-Tempini
et al., 2004). This was not the case for our subjects with
PPAOS. We acknowledge that we did not perform speciﬁc
testing of complex sentence production, for example with the
Northwestern Anagram Test (Weintraub et al., 2009), however
there was no evidence of agrammatism in their spoken language
or in their narrative writing performance, which is a core feature
for the diagnosis. In addition, the neuroanatomical pattern of grey
and white matter loss found in the current study is different from
that reported in the non-ﬂuent/agrammatic variant of PPA as
discussed below.
We have suggested that subjects with isolated AOS may repre-
sent a pathophysiologically distinct group (Josephs et al., 2006a).
Indeed, in comparison with the PPA literature, our subjects with
PPAOS were approximately a decade older at average age of
onset than subjects with non-ﬂuent/agrammatic aphasia. This
age difference was also observed in a recent study that classiﬁed
subjects on the presence or absence of aphasia and AOS (Rohrer
et al., 2010). In fact, only three of our subjects had onset before
65 years. This is important since the pathology of frontotemporal
lobar degeneration is as likely as Alzheimer’s disease with onset
below age 65 (Ratnavalli et al., 2002), whereas Alzheimer’s dis-
ease pathology is much more commonly associated with degen-
erative syndromes above age 65. We did not, however, ﬁnd
evidence for Alzheimer’s disease on PiB-PET scanning in our sub-
jects with PPAOS, suggesting that PPAOS is a distinct syndrome,
pathologically, as well as clinically.
Differentiating PPAOS from the semantic and logopenic variants
of PPA is not particularly difﬁcult because no subject’s proﬁle
across all of the measures, deﬁned by previous or recent consensus
criteria (Neary et al., 1998; Gorno-Tempini et al., 2004, 2011),
would meet criteria for the logopenic or semantic dementia sub-
types of PPA. The issue of whether our subjects with PPAOS will
Figure 3 Statistical stereotactic surface projection maps showing patterns of ﬂuorodeoxyglucose-PET hypometabolism in each of the 12
subjects with PPAOS. Subject numbers are shown to the left of each set of images. Z-score values are colour coded as indicated in the
colour scale (0 = normal; 7 = most abnormal).
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swered at this time. However, even if some do eventually develop
aphasia, which is likely given that PPAOS is a progressive degen-
erative disease, AOS would still have been the presenting and
dominant syndrome during the early-mid course of the disease.
In addition, we cannot rule out the possibility that in at least some
subjects, aphasia will not emerge at any time during the disease
course. In fact, Subject 3 has had illness disease duration of 6
years without emergence of any aphasia. Previous studies have
also reported cases where AOS remained isolated, without the
development of aphasia, for up to 8–10 years (Tebartz van Elst
et al., 2002; Gerstner et al., 2007).
We previously reported an association of AOS with underlying
tau pathologies, particularly with 4 repeat (4R) tau. (Josephs
et al., 2005, 2006a). In that study it appeared that subjects with
what we now call PPAOS were more likely to have the underlying
pathology of progressive supranuclear palsy (Hauw et al., 1994).
This association with tau has subsequently been identiﬁed by other
groups (Deramecourt et al., 2010). It is interesting; however, that
neurological examination did not identify more features commonly
associated with progressive supranuclear palsy in our subjects with
PPAOS, with the exception of Subject 3. This subject had a pure
motor speech disorder for 5.5 years before developing eye move-
ment abnormalities suggestive of underlying progressive supra-
nuclear palsy. The fact that this was the only subject with
disease duration 45 years, and the fact that four subjects with
disease duration of between 4 and 5 years did not show typical
clinical features of progressive supranuclear palsy, suggests that
progressive supranuclear palsy features may be more likely to
emerge at least 5 years into the illness. It remains unclear, how-
ever, whether subjects with PPAOS will develop the full blown
characteristics of progressive supranuclear palsy, since falls in the
ﬁrst year, a symptom typical of progressive supranuclear palsy,
was not reported in any of our 12 subjects with PPAOS and
Figure 4 PiB-PET results for the subjects with PPAOS. (A) Line plot showing the PiB-PET ratio Z-score for the six regions of interest for
each subject with PPAOS. Positive Z-scores represent increased PiB retention compared with control subjects. Only Subject 2 fulﬁlled
criteria for PiB positivity, with the remaining subjects grouped closely together. Ant Cing = anterior cingulate; Post Cing = posterior
cingulate. (B) PiB retention images for Subjects 2 and 8, illustrating increased PiB retention in Subject 2.
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(Litvan et al., 1996). Interestingly though, Subject 3 had executive
dysfunction on neurological testing, with a score of 14 on the
Frontal Assessment Battery. Four other subjects had mild executive
dysfunction as measured by the Frontal Assessment Battery,
although no other subject with PPAOS scored 515. Executive
dysfunction, in particular a Frontal Assessment Battery score of
515, has been associated with progressive supranuclear palsy
(Paviour et al., 2005).
Three of our subjects (Subjects 6, 7 and 10) had limb apraxia
which is a feature of the corticobasal syndrome. However, given
that the chief complaint in these subjects was difﬁculty speaking,
the AOS was moderate, Parkinsonism was absent-mild, and dys-
tonia and myoclonus typical of corticobasal syndrome were absent
at the time of evaluation, these subjects’ most appropriate diag-
nosis was PPAOS. Additional abnormalities were noted in these
three subjects too, including spastic dysarthria, poorer perform-
ance on the Trail Making Test A, a measure of processing
speed, and Frontal Assessment Battery a measure of executive
dysfunction suggesting the evolution of corticobasal syndrome
features in these three subjects. It should be noted though that
the underlying pathology in these subjects could be progressive
supranuclear palsy, since limb apraxia was previously reported in
subjects with AOS and progressive supranuclear palsy pathology
(Josephs et al., 2006a). This would be in keeping with the fact
that while only about half of subjects with corticobasal syndrome
have corticobasal degeneration pathology (Josephs et al., 2006b;
Ling et al., 2010; Lee et al., 2011), many also have progressive
supranuclear palsy pathology (Josephs et al., 2006b; Ling et al.,
2010; Lee et al., 2011). Regardless, the evidence indirectly sug-
gests that the underlying pathology associated with PPAOS is
likely to be tau, either progressive supranuclear palsy or cortico-
basal degeneration (Josephs et al., 2006a; Josephs and Duffy,
2008; Deramecourt et al., 2010). The absence of family history
in all our subjects argues against progranulin gene mutation as a
cause of PPAOS and the impending corticobasal syndrome; not
surprising since progranulin gene mutations appear to be asso-
ciated with aphasia (Mesulam et al., 2007), and are not associated
with tau pathology (Mackenzie, 2007).
Findings from the neuropsychological tests suggest that PPAOS
is a relatively focal neurodegenerative syndrome. Similar to neuro-
psychological ﬁndings in the three variants of PPA (Gorno-Tempini
et al., 2004), we also did not ﬁnd consistent evidence of visuo-
spatial or visuoperceptual deﬁcits in PPAOS. We did ﬁnd some
evidence for executive dysfunction consistent with the neuro-
logical examination. Executive dysfunction appeared to be more
common in the subjects with PPAOS with longer disease duration.
However, executive dysfunction is not only observed in PPAOS
but has also been identiﬁed in subjects with the non-ﬂuent/
agrammatic variant of PPA (Gorno-Tempini et al., 2004). Other
cognitive deﬁcits were absent in PPAOS that differs from the other
PPA variants. For example, there was no evidence for memory loss
or poor calculation skills, which occur in the logopenic aphasia
variant of PPA. The preservation of facial recognition in PPAOS
also differentiates it from the semantic variant of PPA
(Warrington, 1975; Neary et al., 1998; Snowden et al., 2004;
Josephs et al., 2008).
Mild functional decline as measured by the Clinical Dementia
Rating scale was observed in only one subject at the time of
evaluation. This is not to say that there is no functional impair-
ment in subjects with PPAOS. The Clinical Dementia Rating scale
is a metric that was designed to assess functional decline in sub-
jects with episodic memory loss and Alzheimer’s disease (Hughes
et al., 1982). There is no assessment of function related to speech
on the Clinical Dementia Rating scale and even the modiﬁed
Clinical Dementia Rating scale (Knopman et al., 2008) is inad-
equate to assess function related to motor speech impairment.
Mild neurobehavioural abnormalities were noted in three subjects
suggesting that neurobehavioural changes were not a typical fea-
ture of PPAOS and did not affect functional status.
We previously reported that subjects with prominent AOS
showed a pattern of grey matter loss affecting the posterior su-
perior frontal and supplementary motor areas while those with
non-ﬂuent aphasia had more involvement of the posterior inferior
frontal or Broca’s area (Josephs et al., 2006a). In keeping with that
retrospective study, the subjects with PPAOS in this prospective
study had a very focal pattern of grey matter atrophy affecting the
lateral premotor and supplementary motor area. An almost iden-
tical pattern was observed with ﬂuorodeoxyglucose-PET, with
hypometabolism in premotor and supplementary motor areas.
Both analyses therefore point towards the premotor cortex as
the neuroanatomical correlate of PPAOS. There was no evidence
for unilateral involvement in these regions at the group-level, al-
though we did observe asymmetry in some subjects with PPAOS.
However, while cases with right-dominant atrophy and hypome-
tabolism were observed, the majority did show greater involve-
ment of the left hemisphere. Involvement of the premotor region
of the frontal lobe would account for the ﬁndings of executive
dysfunction in some of the subjects with PPAOS, as well as the
poor performance on the action and letter ﬂuency tests. In fact,
these measures have been shown to be associated with frontal
lobe pathology, including premotor cortex (Weiss et al., 2004).
We did not ﬁnd any involvement of the insula cortex, a region
that has been associated with AOS in vascular insults (Dronkers,
1996). The insular cortex, as well as the inferior frontal (superior
opercular) area has been associated with non-ﬂuent/agrammatic
aphasia (Abe et al., 1997; Gorno-Tempini et al., 2004; Grossman
et al., 2004). However, none of these regions were affected in our
group analysis, nor did we see involvement of these areas on the
cortex ID analysis of the ﬂuorodeoxyglucose-PET scan for each
individual subject.
The voxel-based morphometry analysis of white matter volume
showed a more widespread pattern of loss than observed with
grey matter volume. Similar to the grey matter analysis, the lateral
premotor and supplementary motor area white matter was af-
fected. However, white matter volume loss was also observed
extending down into inferior premotor cortex and mid corpus
callosum. These regions were also found to be abnormal with
our diffusion tensor imaging analysis, a more sensitive and speciﬁc
technique for assessing white matter tract pathology. The diffusion
tensor imaging analysis showed degeneration of the body of the
corpus callosum and the superior longitudinal fasciculus, particu-
larly in regions of the premotor cortex with degeneration observed
in ﬁbres extending into the inferior, middle and superior frontal
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sessed PPAOS, degeneration of the body of the corpus callosum
and superior longitudinal fasciculus have been observed in pro-
gressive supranuclear palsy (Whitwell et al., 2011a). This associ-
ation between PPAOS and premotor cortex is biologically plausible
as the premotor area is believed to be involved with motor pro-
gramming. This is remarkable given that AOS was postulated to
be a disorder of programming by Darley when ﬁrst described in
the 1960s (Darley, 1967).
The fact that white matter volume loss was more extensive than
grey matter volume loss raises the possibility that white matter loss
may actually precede grey matter loss, as opposed to white matter
loss occurring via Wallerian degeneration. White matter degener-
ation could be directly related to the deposition of tau. The ﬁnding
of only white matter loss in the inferior frontal lobe, in the absence
of aphasia, suggests that grey matter loss in this region may be
necessary for the development of aphasia. Non-ﬂuent/agrammatic
aphasia has indeed been linked to grey matter loss of the inferior
premotor area (Abe et al., 1997; Gorno-Tempini et al., 2004;
Grossman et al., 2004; Whitwell et al., 2010). The presence of
white matter volume loss in this region would support the sugges-
tion that some of these subjects will later develop aphasia, pre-
sumably as a result of subsequent grey matter involvement.
Longitudinal studies will be needed to test this hypothesis.
We do not have autopsy diagnosis in any of these 12 subjects
with PPAOS. However, the PiB-PET results in our subjects is evi-
dence that amyloid deposition is unlikely to be the aetiology
underlying PPAOS similar to the non-ﬂuent/agrammatic and se-
mantic variants of PPA (Rabinovici et al., 2008). Only one of our
12 subjects was considered PiB-positive and even in this subject it
is unclear whether amyloid is playing any direct role in PPAOS.
This subject was relatively old (age 76) at the time of the scan and
her ﬂuorodeoxyglucose-PET scan was not entirely typical of
Alzheimer’s disease, with minimally less frontal than parietal/tem-
poral hypometabolism that was more prominent on the right but
with sparing of the posterior cingulate gyrus (Foster et al., 2008).
It is therefore possible that this subject has diffuse amyloid that is
characteristic of ageing and unrelated to her PPAOS. Previous re-
ports have shown that the PiB amyloid ligand does indeed bind to
diffuse plaques (Burack et al., 2010; Whitwell et al., 2010). The
currently accepted criteria for a positive PiB-PET scan is also based
on information gained from typical Alzheimer’s dementia subjects
and, therefore, may not generalize to PPAOS.
A syndrome of motor speech impairment in the absence of
aphasia exists that we refer to as PPAOS. It is a relatively homo-
geneous syndrome, and should be diagnosed when AOS is the
sole or predominant presenting sign, especially when the subject’s
chief complaint is one of progressive speech impairment.
Additional neurological, neuropsychological and neurobehavioural
deﬁcits are typically absent, especially early in the disease course.
In some instances, however, especially later in the disease course,
other cognitive, behavioural and motor signs may become evident,
as would be expected, given that PPAOS is a neurodegenerative
disorder. The primary neuroanatomical correlate of PPAOS ap-
pears to be the superior and mid premotor cortex. The underlying
histopathology is unlikely to be amyloid related; the evidence
points more towards tau.
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